Scroll for more


Apr 19, 2018 kenneth mulvany

Funding fundamental change

Dear Benevolent Team, we have come a long way from our earliest ideas about how AI would transform pharmaceutical development in 2013 to our recent announcement of our $115m funding round - one of the largest equity investments in the rapidly emerging AI pharmaceutical sector. I am immensely proud of what we have achieved and of the inspiring talented team of people that have made it happen.

Jan 11, 2017 kenneth mulvany

Is AI morality asleep at the wheel?

In an age where you could soon be legally (and safely) asleep at the wheel thanks to driverless cars will morality in AI go the same way – is the principle of ethics in AI asleep at the wheel?

Dec 1, 2016 kenneth mulvany

Why… …we are called ‘Benevolent’?

We are developing and applying AI technology to enhance and accelerate scientific discovery by turning the world’s mass of highly fragmented scientific information into new insight and useable knowledge that ultimately benefits society.